(Reuters) -A federal jury in Delaware said on Thursday that biotech company Amgen owes competitor Regeneron more than $406 million for engaging in anticompetitive behavior to increase sales of its cholesterol-reduction drug Repatha at the expense of Regeneron's rival drug Praluent. The jury agreed with Regeneron that Amgen unlawfully bundled Repatha with two of its blockbuster anti-inflammatory drugs to persuade pharmacy benefit managers to buy it instead of Praluent. The verdict includes $271.2 million for Regeneron in punitive damages.